Anderson JC, Mattar SG, Greenway FL, Lindquist RJ Measuring ketone bodies for the monitoring of pathologic and therapeutic ketosis. Obes Sci Pract. 2021 May 4;7(5):646-656. doi: 10.1002/osp4.516. eCollection 2021 Oct.
Beck AT, Steer RA, Brown G Beck Depression Inventory-II. Psychol Assess [Internet]. [doi: 10.1037/t00742-000]
Bloem BR, Okun MS, Klein C Parkinson's disease. Lancet. 2021 Jun 12;397(10291):2284-2303. doi: 10.1016/S0140-6736(21)00218-X. Epub 2021 Apr 10.
Boertien JM, Pereira PAB, Aho VTE, Scheperjans F Increasing Comparability and Utility of Gut Microbiome Studies in Parkinson's Disease: A Systematic Review. J Parkinsons Dis. 2019;9(s2):S297-S312. doi: 10.3233/JPD-191711.
Borghammer P, Van Den Berge N Brain-First versus Gut-First Parkinson's Disease: A Hypothesis. J Parkinsons Dis. 2019;9(s2):S281-S295. doi: 10.3233/JPD-191721.
Choi A, Hallett M, Ehrlich D Nutritional Ketosis in Parkinson's Disease - a Review of Remaining Questions and Insights. Neurotherapeutics. 2021 Jul;18(3):1637-1649. doi: 10.1007/s13311-021-01067-w. Epub 2021 Jul 7. Erratum In: Neurotherapeutics. 2021 Jul 26;:
Chrysohoou C, Panagiotakos DB, Pitsavos C, Das UN, Stefanadis C Adherence to the Mediterranean diet attenuates inflammation and coagulation process in healthy adults: The ATTICA Study. J Am Coll Cardiol. 2004 Jul 7;44(1):152-8. doi: 10.1016/j.jacc.2004.03.039.
Davis C, Bryan J, Hodgson J, Murphy K Definition of the Mediterranean Diet; a Literature Review. Nutrients. 2015 Nov 5;7(11):9139-53. doi: 10.3390/nu7115459.
Freeman JM, Kossoff EH, Hartman AL The ketogenic diet: one decade later. Pediatrics. 2007 Mar;119(3):535-43. doi: 10.1542/peds.2006-2447.
Garcia-Rodriguez D, Gimenez-Cassina A Ketone Bodies in the Brain Beyond Fuel Metabolism: From Excitability to Gene Expression and Cell Signaling. Front Mol Neurosci. 2021 Aug 27;14:732120. doi: 10.3389/fnmol.2021.732120. eCollection 2021.
Gasior M, Rogawski MA, Hartman AL Neuroprotective and disease-modifying effects of the ketogenic diet. Behav Pharmacol. 2006 Sep;17(5-6):431-9. doi: 10.1097/00008877-200609000-00009.
GBD 2016 Parkinson's Disease Collaborators Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018 Nov;17(11):939-953. doi: 10.1016/S1474-4422(18)30295-3. Epub 2018 Oct 1. Erratum In: Lancet Neurol. 2021 Dec;20(12):e7.
Harms AS, Ferreira SA, Romero-Ramos M Periphery and brain, innate and adaptive immunity in Parkinson's disease. Acta Neuropathol. 2021 Apr;141(4):527-545. doi: 10.1007/s00401-021-02268-5. Epub 2021 Feb 8.
Hirayama M, Ohno K Parkinson's Disease and Gut Microbiota. Ann Nutr Metab. 2021;77 Suppl 2:28-35. doi: 10.1159/000518147. Epub 2021 Sep 9.
Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age Ageing. 1997 Sep;26(5):353-7. doi: 10.1093/ageing/26.5.353.
Lewis SJ, Heaton KW Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997 Sep;32(9):920-4. doi: 10.3109/00365529709011203.
Myette-Cote E, Soto-Mota A, Cunnane SC Ketones: potential to achieve brain energy rescue and sustain cognitive health during ageing. Br J Nutr. 2022 Aug 14;128(3):407-423. doi: 10.1017/S0007114521003883. Epub 2021 Sep 28.
Nagpal R, Neth BJ, Wang S, Craft S, Yadav H Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer's disease markers in subjects with mild cognitive impairment. EBioMedicine. 2019 Sep;47:529-542. doi: 10.1016/j.ebiom.2019.08.032. Epub 2019 Aug 30.
Nagpal R, Shively CA, Register TC, Craft S, Yadav H Gut microbiome-Mediterranean diet interactions in improving host health. F1000Res. 2019 May 21;8:699. doi: 10.12688/f1000research.18992.1. eCollection 2019.
Norwitz NG, Hu MT, Clarke K The Mechanisms by Which the Ketone Body D-beta-Hydroxybutyrate May Improve the Multiple Cellular Pathologies of Parkinson's Disease. Front Nutr. 2019 May 14;6:63. doi: 10.3389/fnut.2019.00063. eCollection 2019.
Nygaard HB, Kent BA, Stager S, et al A phase 1B multiple ascending dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of a medium chain triglyceride supplement in Alzheimer's disease: Brain energy rescue interventions to treat or delay Alzheimer's disease. Alzheimer's & Dementia. 2020;16(S10). doi:10.1002/alz.037960
Nylen K, Likhodii S, Burnham WM The ketogenic diet: proposed mechanisms of action. Neurotherapeutics. 2009 Apr;6(2):402-5. doi: 10.1016/j.nurt.2009.01.021.
Ohlsson B, Roth B, Larsson E, Hoglund P Calprotectin in serum and zonulin in serum and feces are elevated after introduction of a diet with lower carbohydrate content and higher fiber, fat and protein contents. Biomed Rep. 2017 Apr;6(4):411-422. doi: 10.3892/br.2017.865. Epub 2017 Feb 22.
Olson CA, Vuong HE, Yano JM, Liang QY, Nusbaum DJ, Hsiao EY The Gut Microbiota Mediates the Anti-Seizure Effects of the Ketogenic Diet. Cell. 2018 Jun 14;173(7):1728-1741.e13. doi: 10.1016/j.cell.2018.04.027. Epub 2018 May 24. Erratum In: Cell. 2018 Jul 12;174(2):497.
Paoli A, Bianco A, Damiani E, Bosco G Ketogenic diet in neuromuscular and neurodegenerative diseases. Biomed Res Int. 2014;2014:474296. doi: 10.1155/2014/474296. Epub 2014 Jul 3.
Silva GG, Green KT, Dutilh BE, Edwards RA SUPER-FOCUS: a tool for agile functional analysis of shotgun metagenomic data. Bioinformatics. 2016 Feb 1;32(3):354-61. doi: 10.1093/bioinformatics/btv584. Epub 2015 Oct 9.
van Delft R, Lambrechts D, Verschuure P, Hulsman J, Majoie M Blood beta-hydroxybutyrate correlates better with seizure reduction due to ketogenic diet than do ketones in the urine. Seizure. 2010 Jan;19(1):36-9. doi: 10.1016/j.seizure.2009.10.009. Epub 2009 Dec 3.
Washburn RA, Zhu W, McAuley E, Frogley M, Figoni SF The physical activity scale for individuals with physical disabilities: development and evaluation. Arch Phys Med Rehabil. 2002 Feb;83(2):193-200. doi: 10.1053/apmr.2002.27467.
Wlodarek D Role of Ketogenic Diets in Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease). Nutrients. 2019 Jan 15;11(1):169. doi: 10.3390/nu11010169.
Wood DE, Lu J, Langmead B Improved metagenomic analysis with Kraken 2. Genome Biol. 2019 Nov 28;20(1):257. doi: 10.1186/s13059-019-1891-0.
Yuan X, Wang J, Yang S, Gao M, Cao L, Li X, Hong D, Tian S, Sun C Effect of the ketogenic diet on glycemic control, insulin resistance, and lipid metabolism in patients with T2DM: a systematic review and meta-analysis. Nutr Diabetes. 2020 Nov 30;10(1):38. doi: 10.1038/s41387-020-00142-z.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.